Citadel Advisors LLC lowered its position in shares of Acceleron Pharma Inc (NASDAQ:XLRN) by 62.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 84,819 shares of the biopharmaceutical company’s stock after selling 138,893 shares during the quarter. Citadel Advisors LLC’s holdings in Acceleron Pharma were worth $3,599,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Point72 Asset Management L.P. bought a new stake in Acceleron Pharma during the third quarter valued at $2,721,000. Vanguard Group Inc. raised its holdings in shares of Acceleron Pharma by 6.1% during the second quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock valued at $61,663,000 after purchasing an additional 116,705 shares during the period. Artisan Partners Limited Partnership acquired a new position in shares of Acceleron Pharma during the third quarter valued at about $11,938,000. California State Teachers Retirement System raised its holdings in shares of Acceleron Pharma by 5.2% during the second quarter. California State Teachers Retirement System now owns 56,795 shares of the biopharmaceutical company’s stock valued at $1,726,000 after purchasing an additional 2,826 shares during the period. Finally, Prudential Financial Inc. acquired a new position in shares of Acceleron Pharma during the third quarter valued at about $3,024,000. 90.13% of the stock is currently owned by institutional investors and hedge funds.
Shares of Acceleron Pharma Inc (NASDAQ XLRN) opened at $42.91 on Friday. Acceleron Pharma Inc has a fifty-two week low of $24.37 and a fifty-two week high of $46.93.
In related news, SVP Christopher Rovaldi sold 11,000 shares of the company’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $45.00, for a total value of $495,000.00. Following the sale, the senior vice president now owns 35,701 shares in the company, valued at approximately $1,606,545. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jean George sold 105,122 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $35.73, for a total transaction of $3,756,009.06. Following the completion of the sale, the director now owns 1,250 shares in the company, valued at approximately $44,662.50. The disclosure for this sale can be found here. Insiders sold a total of 146,021 shares of company stock worth $5,529,598 in the last 90 days. 3.90% of the stock is currently owned by company insiders.
XLRN has been the topic of several research reports. BidaskClub upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Thursday, February 15th. Credit Suisse Group set a $51.00 price objective on shares of Acceleron Pharma and gave the company a “buy” rating in a report on Tuesday, November 14th. HC Wainwright upped their price objective on shares of Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. Cann reiterated a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th. Finally, Oppenheimer reiterated a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $44.81.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/24/acceleron-pharma-inc-xlrn-shares-sold-by-citadel-advisors-llc.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc (NASDAQ:XLRN).
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.